4.63 USD
▲+0.02+3.12%
盘后 4.41 -1.78%
2026-08-03
市值
$14.85M
市盈率
—
EPS
-11.84
股息率
—
52 周区间
3.29 – 20.00
成交量
37.62K
Beta
1.42
目标价
15.50
52W 低 3.2952W 高 20.00
价格走势
公司简介
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s...